Improving ObsQoR-11 With Continuous Wound Infusion Versus Intrathecal Morphine After Elective Cesarean Delivery

• Status: Not yet recruiting
• Trial end date: 2023-11-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this prospective randomized double-blinded and controlled study is to evaluate the quality of recovery after elective cesarean delivery using the Obstetric Quality-of-Recovery-11 (ObsQoR-11) score at 24 hours between patients receiving intrathecal morphine (ITM group) compared to patients receiving a ropivacaine continuous wound infusion (CWI group).

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Ciusss de L'Est de l'Île de Montréal
• Treatments: Morphine; Ropivacaine

Criteria

Inclusion Criteria:

• American Society of Anesthesiologists status I and II

• Maternal age above 18 years' old

• Elective cesarean delivery

• Spinal anesthesia

• At least 37 weeks of gestational age

• French-speaking patients (able to read and sign the consent form)

Exclusion Criteria:

• Chronic pain

• Chronic usage of any opioids

• Cardiopathy

• Unexpected difficult spinal anesthesia requiring general anesthesia or unsatisfactory sensory blockade

• Unexpected complications requiring strong hemodynamic support (transfusions, volume challenges, multiple vasopressors, inotropic drugs…) or requiring anti-hypertensive medication (including magnesium)

• Any contraindication (e.g. coagulopathy) or patient's refusal for spinal anesthesia

• Morbid obesity (BMI > 40 at the time of delivery)

• Active labour

• Emergency CD

• Fetal abnormality or prematurity (< 37 weeks of gestational age)

• Multiple gestation

• Inability to cooperate due to language or physical/mental incapacity